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Preeclampsia is a disease characterized by increased antian-giogenesis and inflammation. Although clearly the onset 
of the disease is of placental origin, a network of unfavor-
able responses is released. Soluble variants of the vascular 
endothelial growth factor receptor 1 and of the tumor growth 
factor-β coactivating receptor endoglin are involved in the 
antiangiogenic response, yet the inflammatory response is 
complex involving multiple cytokines. Clearly, cytokines such 
as interleukin-6 and tumor necrosis factor-α are elevated in 
preeclampsia.1 These cytokines support the expression of the 
acute-phase protein C-reactive protein (CRP). Regularly pro-
duced in the liver, CRP has also been found in amniotic fluid. 
This suggested local production sites, which were specified 
in the current study by Parchim et al.2 As is binds to surface 
phosphocholine, it activates the complement system.
For a long time, a role of CRP in preeclampsia has been 
conceived. Studies exploring genetic variants of CRP linked to 
adverse cardiovascular outcomes could identify an association 
of these variants to preeclampsia in independent populations.3 
Several studies suggested preeclampsia to be related to CRP 
levels and a metaanalysis exploring studies with a prospec-
tive setup to correlate CRP concentrations with the subsequent 
occurrence of preeclampsia, a highly significant relationship 
was identified with an important modifier being body mass 
index.4,5 As CRP is found elevated before disease onset,4,6 a 
pathomechanistic role could be considered. However, the func-
tional role of CRP in preeclampsia had remained enigmatic.
In several elegant experiments, Parchim et al2 unravel a 
mechanism which might account for placental and also for 
kidney injury and arterial hypertension in preeclamptic dis-
ease. The authors demonstrate the placenta as production site 
for CRP in addition to the liver in nonpregnant conditions. In a 
classical setup, they infused CRP at concentrations comparable 
to those found in the circulation of preeclamptic women into 
mice, which led to hypertension, glomerular damage, and asso-
ciated proteinuria as well as to features of premature athero-
sclerosis within the placentas. This was also linked to enhanced 
soluble vascular endothelial growth factor receptor 1 secretion. 
As the response was only seen in pregnant mice, in these short-
term experiments the placenta seems to be critical.
To identify the signaling pathway, the authors referred to the 
observation that CRP binds to phosphocholine. As the placenta 
is one of the tissues to which a phosphocholine transferase 
activity has been localized, posttranslational phosphocholine 
modification might apply. As the neurokinin 3 receptor is 
thought to be also involved in hypertension in pregnancy and 
phosphocholinated neurokinin B preferentially binds to this 
receptor, this pathway was explored. In the mice, neurokinin 3 
receptor blockade improved the tissue lesions within the kidney 
and within the placenta, as well as soluble vascular endothelial 
growth factor receptor 1 levels on CRP exposure. Knockdown 
of the phosphocholine transferase enzyme production resem-
bled these findings. They found CRP and neurokinin B colocal-
ized in villous syncytiotrophoblast cells and even identified a 
link between CRP, neurokinin 3 receptor signaling, and sFlt-1 
secretion in human placental villus explants.
These findings are of interest for various reasons. First, 
they provide a link between proinflammatory markers but also 
maternal conditions such as an elevated body mass index with 
enhanced CRP levels and development of preeclampsia. This 
is exiting because inflammation is considered a secondary 
event in most forms of preeclampsia, yet high body weight 
might arise as an independent initial event in the pathogenesis 
of preeclampsia as it predisposes to higher CRP levels. Yet 
beyond pregnancy, if exposure to CRP is prolonged beyond 
acute infectious defense responses, and as more conditions 
and organs might be identified as phosphocholine transferase 
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Figure. Placental dysfunction or fat tissue leads to the 
expression of the C-reactive protein in the liver or the placenta. 
C-reactive protein binds to phosphocholins which are transferred 
to neurokinin B thereby enhancing activation of the neurokinin 
3 receptor. This leads to organ damage and arterial hypertension. 
IL indicates interleukin; and TNF, tumor necrosis factor.
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targets such as the kidneys, the pathomechanistic role of CRP 
in even low level inflammation may deserve increased atten-
tion. The mechanism and the signaling pathway demonstrated 
in this article might even lead to future clinical applications. 
This is an intriguing example of how a putative predictor of 
disease turns into an attractive therapeutic target (Figure).
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